Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of JMT601 injection in primary membranous nephropathy
CTR20252308Phase 2Active
- Sponsor
- Shanghai Jinmante Biotechnology Co., Ltd.
- Start
- Sep 2025
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of JMT601 in idiopathic membranous glomerulonephritis (IMG), sponsored by Shanghai Jinmante Biotechnology Co., Ltd.. Started Sep 2025; status: active.
02
Drugs
JMT601
03
Conditions
idiopathic membranous glomerulonephritis (IMG)
Beyond the preview
Go deeper on CTR20252308.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252308.